Analyst Price Targets — QGEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 14, 2026 8:35 am | Harry Gillis | Berenberg Bank | $45.50 | $41.44 | TheFly | Qiagen downgraded to Hold from Buy at Berenberg |
| June 25, 2026 8:39 am | — | Kepler Capital | $38.60 | $38.73 | TheFly | Qiagen initiated with a Hold at Kepler Cheuvreux |
| June 23, 2026 8:24 am | — | Morgan Stanley | $42.00 | $36.28 | TheFly | Qiagen upgraded to Overweight from Equal Weight at Morgan Stanley |
| May 18, 2026 10:43 am | — | Stifel Nicolaus | $36.00 | $32.98 | TheFly | Qiagen price target lowered to $36 from $50 at Stifel |
| April 30, 2026 1:06 pm | Jan Koch | Deutsche Bank | $43.00 | $33.89 | TheFly | Qiagen price target lowered to $43 from $54 at Deutsche Bank |
| April 29, 2026 9:35 am | Luke Sergott | Barclays | $38.00 | $34.02 | TheFly | Qiagen price target lowered to $38 from $44 at Barclays |
| April 29, 2026 9:04 am | — | Robert W. Baird | $43.00 | $34.02 | TheFly | Qiagen upgraded to Outperform from Neutral at Baird |
| April 14, 2026 10:38 am | — | Barclays | $44.00 | $41.91 | TheFly | Qiagen downgraded to Equal Weight from Overweight at Barclays |
| February 9, 2026 11:56 am | — | UBS | $52.00 | $50.95 | TheFly | Qiagen price target raised to $52 from $50 at UBS |
| February 6, 2026 2:50 pm | Cathy Ramsey Schulte | Robert W. Baird | $53.00 | $51.17 | TheFly | Qiagen price target raised to $53 from $48.42 at Baird |
Latest News for QGEN
GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United States. More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May, along with another 7,000…
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three…
VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel, establishing a comprehensive bloodstream infection testing offering on the QIAstat-Dx platform in Europe. The new QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and…
Qiagen N.V. is rated a Buy, supported by new product launches and automation initiatives poised to drive revenue growth. QGEN's QIAspirant Connect and partnerships like Inpeco/Diasorin and NVIDIA AI collaboration are expected to offset sluggish QuantiFERON demand and accelerate sales. Management reaffirms 1–2% CER sales growth for FY2026, with new launches already receiving orders and broad market access in sample…
Qiagen is drawing early takeover interest from buyout firms, including EQT AB , Advent and KKR , Bloomberg News said on Thursday, citing people familiar with the matter.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for QGEN.
Senate Trading
No Senate trades found for QGEN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.